

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2023.

Commission File Number: 001-40627

SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)

Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 12, 2023

SOPHiA GENETICS SA

By: /s/ Daan van Well
Name: Daan van Well
Title: Chief Legal Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Investor presentation Building a Data-Driven World dated May 12, 2023



Building a Data-Driven World

Dr. Jurgi CAMBLONG

Chief Executive Officer & Co-Founder

May 12, 2023



Cautionary Notices

This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

No offer to sell or buy

This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Other material information

This presentation does not contain all material information about SOPHiA GENETICS SA and its subsidiaries. No representations or warranties (expressed or implied) are made regarding the completeness of the information contained in this presentation. Refer to our Securities and Exchange Commission filings for additional information about us.

Market and industry data

This presentation contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Our estimates of addressable market (or similar concepts) are primarily based on epidemiological data, including incidence and prevalence estimates of addressable populations, as well as a range of price assumptions for our products taking into account differences in panel sizes, which may change over time. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty.

Research use only

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

Snapshot of SOPHiA Genetics



We are a category defining software company on a mission to
Democratize Data-Driven Medicine

The Emergence of the Cloud and AI


have transformed countless of industries



BUT,
Healthcare
is lagging



Healthcare Data are Complex, Siloed and Diverse




BC, blood count; H&E, hematoxylin and eosin; MRD, minimal residual disease; PS, performance status.

Creating Network Effects in Healthcare is Difficult

given non-standardized methods and sensitive data



to better and equally serve every patient around the world



Significantly Important for Key Diseases

driven by genomic alterations

Cancer


>25 Million New
Cancer Cases per Year¹

Rare Diseases

~5% of the global population
suffers from a Rare Disease²


Multimodal Data Brings Objectivity

into human biology and diseases




Empowering Clinical and BioPharma Customers

driving the data flywheel to benefit patients




Transforming Healthcare through Strategic Collaborations


- Generate robust insights
- Break data silos
- **Create a collective intelligence**
- Accelerate adoption of precision medicine



Total Addressable Market is Significant



Clinical TAM Supported by a Broad Set of Disease Indications



Growing with our Customers Volume

via a consumption based SaaS model



© SOPHiA GENETICS 2023

BioPharma TAM is an Emerging Opportunity

BioPharma TAM
\$14bn

Discovery

Applying AI and ML to the proprietary data of our customers

Development

Powering predictive algorithms for better targeted drugs

Deployment

Entering markets worldwide with new solutions via our network

Key Financial Metrics

750+

Total customers ⁽¹⁾

430+

Core Genomics customers ⁽¹⁾

1.2 million+

Genomic Profiles Analyzed ⁽¹⁾

~77,000+

Genomic profiles analyzed in 1Q 2023 ⁽¹⁾

30% - 35%

2023 constant currency ex COVID revenue growth guidance ⁽²⁾

37%

1Q2023 constant currency ex COVID revenue growth ⁽²⁾

69% | 73%

Q1 2023 IFRS gross profit margin | adjusted gross profit margin ⁽³⁾

~\$162M

Cash, cash equivalents, & term deposits ⁽¹⁾

FN 1: Represents statistic as of 03/31/2023. **FN 2:** The Company is unable to provide a reconciliation of forward-looking constant currency revenue growth excluding COVID-19-related revenue to Revenue, the most comparable IFRS financial measure, due to the inherent difficulty in forecasting and quantifying the impact of foreign currency translation. **FN 3:** Please refer to appendix for IFRS to adjusted gross margin reconciliation.



Thank You



Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin for the Three Months Ended March 31, 2023

Amounts in USD thousands

(unaudited)

Three months ended March 31, 2023

Revenue	\$13,966
Cost of revenue	(4,272)
Gross profit	\$9,694
Amortization of capitalized research and development expenses ⁽¹⁾	432
Adjusted gross profit	\$10,126
Gross profit margin	69%
Amortization of capitalized research and development expenses ⁽¹⁾	4%
Adjusted gross profit margin	73%

Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth and Constant Currency Revenue Growth Excluding COVID-19-Related Revenue

(Amounts in USD thousands)	2022	2023
	Q1	Q1
Revenue		
Reported Revenue	\$10,861	\$13,966
<i>Y-o-Y Growth</i>	21%	29%
Current Period Constant Currency Impact		618
Constant Currency Revenue	\$10,861	\$14,584
<i>Y-o-Y Growth</i>		34%
COVID-19 Revenue	(331)	(125)
Constant Currency Impact on COVID-19 Revenue		5
Constant Current Revenue Excluding COVID-19 Revenue	\$10,530	\$14,464
<i>Y-o-Y Growth</i>		37%

Notes to the Reconciliation of IFRS to Adjusted Financials

- (1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.
- (2) Damaged inventory write-off consists of expenses associated with the write-off of inventory that were damaged as a result of a refrigeration equipment malfunction. These expenses are not expected to be a recurring event in our business, but we expect such expenses could still be incurred from time to time.
- (3) Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments.
- (4) Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy.
- (5) Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense, but pensions remain a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future.
- (6) Non-recurring IPO-related expenses represent expenses incurred for our initial public offering that were not capitalized and are not expected to be recurring during the ordinary course of our business.

Consistent Growth in Analysis Volume

accelerated momentum of analysis volume conducted on our platform going into 2023

